Abbott Laboratories

Strategic intent

Abbott Laboratories is a diversified multinational healthcare company that develops, manufactures, and sells medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals.

Key market signals

• 2026-04: Completed the $21 billion acquisition of Exact Sciences, significantly expanding its oncology diagnostics portfolio.
• 2026-04: Received FDA clearance and CE Mark for Ultreon 3.0, an AI-powered coronary imaging platform.
• 2026-04: Ordered by an Illinois jury to pay $70 million in damages in a necrotizing enterocolitis (NEC) baby formula lawsuit.
• 2026-03: S&P Global Ratings downgraded Abbott's issuer credit rating to 'A+' from 'AA-' following the Exact Sciences acquisition.
• 2024-07: A Missouri jury awarded $495 million in an NEC baby formula lawsuit against Abbott (part of ongoing nationwide litigation).

Financial health

• Q1 2026 net sales were $11.16 billion, representing a 7.8% year-over-year increase (https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2026-results-updates-guidance-to-reflect-acquisition-of-exact-sciences-302118123.html).
• Full-year 2025 revenue was reported at $44.3 billion with an operating income of $8.05 billion (https://en.wikipedia.org/wiki/Abbott_Laboratories).
• Following the $21 billion acquisition of Exact Sciences in Q1 2026, S&P Global Ratings downgraded Abbott's credit rating to 'A+' from 'AA-' due to increased leverage (https://www.spglobal.com/ratings/en/research/articles/260324-abbott-laboratories-downgraded-to-a-from-aa-on-close-of-exact-sciences-acquisition-outlook-stable).

Impact & compliance

Legal & risks

Over the last 24 months, Abbott has faced extensive litigation regarding its cow's milk-based premature infant formulas (Similac), with plaintiffs alleging the products cause necrotizing enterocolitis (NEC). Notable outcomes include a $495 million jury verdict in Missouri in July 2024 and a $70 mill

Classifications

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.